Advertisement
The company presentations address recent product launches, developmentpipelines, and market strategies that these businesses are deploying toachieve long-term, faster-than-market, growth rates across their businesses.They include new ways the company is addressing chronic diseases related tocardiovascular disease, metabolic disease and ophthalmology in a morecomprehensive way; new surgical products to address the growing demand inareas like orthopaedics, obesity and minimally invasive surgery; and thecontinuing application of superior science and technology to the company'sbroad range of consumer health care products.
Advertisement
"Johnson & Johnson remains a company committed to serving unmet healthcare needs with superior science and technology, while growing our businessesprofitably for the long-term," said Dominic Caruso, Vice President, Finance,and Chief Financial Officer for Johnson & Johnson. "The businesses we arehighlighting at today's meeting -- the world's largest medical technologybusiness and premier consumer health care company -- develop importantinnovations for the benefit of patients, customers and shareholders."
World's Largest Medical Technology Business
In 2007, Johnson & Johnson's Medical Devices & Diagnostics (MD&D) segmentgenerated $21.7 billion in sales across its seven franchises, which was 35percent of the company's total sales. Excluding a decline in the company'sdrug-eluting stent business, the segment grew almost 10 percent operationally.
The MD&D segment's seven franchises are organized into Surgical Care andComprehensive Care Groups, and consist of DePuy, Ethicon, Ethicon Endo-Surgeryin Surgical Care, and Cordis, Ortho-Clinical Diagnostics, Diabetes Care andJohnson & Johnson Vision Care in Comprehensive Care. These franchises competein a global MD&D market valued at approximately $270 billion.
Surgical Care
Sheri McCoy, Worldwide Chairman of the Surgical Care Group, describes herbusiness this way, "We have three well-established, solid and growingfranchises that are the market leaders in their respective categories. We arewell-positioned with approved products and a robust pipeline to meet the needsof patients and surgeons alike, in high-growth areas like orthopaedics,obesity, and core surgical products like advanced energy-based instruments andbiosurgicals."
In their presentations today, McCoy and her leadership team are outliningfour growth strategies for the Surgical Care Group:
Comprehensive Care
Don Casey, Worldwide Chairman of the Comprehensive Care Group, describeshis business this way: "We are focused on two core priorities," says Casey."Our first priority is to maximize the potential of our current franchises.We've been able to deliver an aggressive pipeline in 2007 and 2008 withseveral major launches, and we expect most of the franchises to continue todeliver this kind of innovation in the next few years to help continue drivinggrowth. Our second priority is delivering on our vision for ComprehensiveCare by developing patient-centric solutions to address chronic diseases."
The Comprehensive Care Group and its business leaders are addressing thegroup's two core priorities in its presentations today:
In a
